Our study showed the best survival outcome in type I TME (PD-L1+/TIL+) similar to the findings in melanoma, as well as in HNSCC, which showed the most favorable prognosis in type I (PD-L1+/TIL+) and type IV (PD-L1−/TIL+) [23,34,35,37]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.